The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
- 28 January 2003
- journal article
- clinical trial
- Published by Wiley in Haemophilia
- Vol. 9 (1), 38-49
- https://doi.org/10.1046/j.1365-2516.2003.00708.x
Abstract
Background: B‐domain‐deleted recombinant factor VIII (BDDrFVIII) was developed when the B‐domain was found to be redundant for maintaining haemostasis. This allows formulation of the final product wi...Keywords
This publication has 32 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- B-domain deleted recombinant factor VIII formulation and stabilitySeminars in Hematology, 2001
- Viral safety of B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- Measurement of factor VIII activity of B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- Structural and functional characterization of B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patientsSeminars in Hematology, 2001
- The manufacturing process for B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Structure of human factor VIIINature, 1984
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984